Tue Hodal

Tue Hodal brings over 25 years of extensive experience in the biotech and pharmaceutical sectors, with a track record of scaling operations across both large corporations and high-growth startups. He is Melt&Marble's first Chief Technology Officer (CTO), appointed to lead the company's scale-up strategy as it prepares for large-scale commercial production.

Career History

• Chief Technology Officer at Bacthera, a company specializing in bacterial biotherapeutics (most recent prior role)
• Chief Manufacturing Officer at Bacthera (promoted July 2021)
• Senior roles at Novo Nordisk
• Senior roles at Chr. Hansen
• Senior roles at Lundbeck

Hodal has over 15 years' experience leading different parts of the supply chain in the pharmaceutical industry, from production and global planning to engineering and operational excellence, and has more than five years of consultancy experience within the pharma and oil & gas industries. He was appointed Project Director at Bacthera in November 2019, after supporting Chr. Hansen in setting up the joint venture.

In his new role at Melt&Marble, Hodal will focus on optimizing bioprocesses and downstream operations to facilitate large-scale, economically sustainable production of precision-fermented fats. Melt&Marble is a manufacturer of precision-fermented fats that has developed a proprietary technology designed to engineer yeast metabolism to produce tailored fats for use in food and personal care products. Melt&Marble recently secured €2.76m in EU grants and announced a partnership with Finnish food and dairy giant Valio to explore development of next-generation plant-based products.

What Tue Hodal could bring to Chief Technology Officer at Melt&Marble: Hodal's appointment signals that Melt&Marble values his expertise in manufacturing scale-up and bioprocess optimization—critical capabilities as the company transitions from laboratory proof-of-concept to commercial-scale production. His experience spanning both pharmaceutical giants (Novo Nordisk, Lundbeck) and biotechnology startups positions him uniquely to navigate the operational challenges of scaling precision fermentation while managing costs. His track record at Bacthera in live biotherapeutics manufacturing suggests he understands complex regulatory environments and the complexities of producing biologically derived products at scale, directly applicable to Melt&Marble's mission of bringing sustainable designer fats to market.